Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The Recursive Division Tree (RDT) algorithm is a mathematical process for measuring the logarithmic height of positive integers. For any integer ( n \ge 2 ), it recursively divides by logarithm-based ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

The 2025 Florida Python Challenge yielded 294 Burmese pythons, the most since the challenge began. Taylor Stanberry won the Ultimate Grand Prize of $10,000 for capturing 60 pythons. A total of 294 ...

A large albino Burmese python, nicknamed "Nanners," was captured in Prosperity, South Carolina, after weeks on the loose. Local resident Warren Gallman and friends caught the snake, which had been ...

Residents of downtown Los Angeles were recently shocked to discover a gigantic 20-foot python in a dumpster near an apartment complex. Locals originally thought the snake was fake, but further ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Burmese pythons, while non-venomous, can inflict painful bites with sharp teeth, causing significant bleeding. The annual Florida Python Challenge offers over $25,000 in prizes to hunters removing ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...